Literature DB >> 7471124

Phase II study of L-asparaginase in the treatment of pancreatic carcinoma.

H E Lessner, S Valenstein, R Kaplan, P DeSimone, A Yunis.   

Abstract

L-Asparaginase was given to ten patients with advanced nonresectable pancreatic carcinoma because of the demonstration of in vitro sensitivity of the tumor to the drug. No therapeutic value was demonstrated for L-asparaginase. Toxicity was significant, mainly as evidenced by increasing mental confusion and early signs of a coagulopathy. On the basis of this limited study, L-asparaginase seems to have no value in advanced pancreatic carcinoma. The usefulness of L-asparaginase as primary therapy in patients with less advanced disease remains to be determined.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7471124

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  9 in total

1.  Glutaminolysis and carcinogenesis of oral squamous cell carcinoma.

Authors:  Marcel Cetindis; Thorsten Biegner; Adelheid Munz; Peter Teriete; Siegmar Reinert; Martin Grimm
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-02-07       Impact factor: 2.503

Review 2.  Glutamine addiction: a new therapeutic target in cancer.

Authors:  David R Wise; Craig B Thompson
Journal:  Trends Biochem Sci       Date:  2010-08       Impact factor: 13.807

Review 3.  Amino acid metabolism in hematologic malignancies and the era of targeted therapy.

Authors:  Yoko Tabe; Philip L Lorenzi; Marina Konopleva
Journal:  Blood       Date:  2019-08-15       Impact factor: 22.113

Review 4.  Altered energy metabolism in cancer: a unique opportunity for therapeutic intervention.

Authors:  Yi Zhang; Jin-Ming Yang
Journal:  Cancer Biol Ther       Date:  2012-11-28       Impact factor: 4.742

5.  MAPK signaling regulates c-MYC for melanoma cell adaptation to asparagine restriction.

Authors:  Gaurav Pathria; Sachin Verma; Jun Yin; David A Scott; Ze'ev A Ronai
Journal:  EMBO Rep       Date:  2021-02-08       Impact factor: 8.807

Review 6.  Cancer metabolism: current perspectives and future directions.

Authors:  C Muñoz-Pinedo; N El Mjiyad; J-E Ricci
Journal:  Cell Death Dis       Date:  2012-01-12       Impact factor: 8.469

Review 7.  Drug-induced amino acid deprivation as strategy for cancer therapy.

Authors:  Marcus Kwong Lam Fung; Godfrey Chi-Fung Chan
Journal:  J Hematol Oncol       Date:  2017-07-27       Impact factor: 17.388

8.  Translational reprogramming marks adaptation to asparagine restriction in cancer.

Authors:  Joo Sang Lee; Erez Hasnis; Gaurav Pathria; Kristofferson Tandoc; David A Scott; Sachin Verma; Yongmei Feng; Lionel Larue; Avinash D Sahu; Ivan Topisirovic; Eytan Ruppin; Ze'ev A Ronai
Journal:  Nat Cell Biol       Date:  2019-11-18       Impact factor: 28.824

9.  Therapeutic Assessment of Targeting ASNS Combined with l-Asparaginase Treatment in Solid Tumors and Investigation of Resistance Mechanisms.

Authors:  Verena Apfel; Damien Begue; Valentina Cordo'; Laura Holzer; Laetitia Martinuzzi; Alexandra Buhles; Grainne Kerr; Ines Barbosa; Ulrike Naumann; Michelle Piquet; David Ruddy; Andreas Weiss; Stephane Ferretti; Reinaldo Almeida; Debora Bonenfant; Luca Tordella; Giorgio G Galli
Journal:  ACS Pharmacol Transl Sci       Date:  2021-01-13
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.